阿美特克 (AME) 2023 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good day, and thank you for standing by. Welcome to the Fourth Quarter 2023 AMETEK Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

    各位好,感謝您稍候。歡迎參加 AMETEK 2023 年第四季財報電話會議。(接線員指示)請注意,今天的會議將被錄音。

  • I would now like to hand the conference over to your speaker, Kevin Coleman, Vice President of Investment Relations and Treasurer. You may begin.

    現在我想把會議交給今天的講者,投資人關係副總裁兼財務長 Kevin Coleman。您可以開始了。

  • Kevin C. Coleman - VP of IR & Treasurer

    Kevin C. Coleman - VP of IR & Treasurer

  • Thank you, Tanya. Good morning, and thank you for joining us for AMETEK's Fourth Quarter 2023 Earnings Conference Call. With me today are Dave Zapico, Chairman and Chief Executive Officer; Bill Burke, Executive Vice President and Chief Financial Officer; and Dalip Puri, Senior Vice President, Operational Finance.

    謝謝你,Tanya。各位早安,感謝各位參加 AMETEK 2023 年第四季財報電話會議。今天與我一同出席的有董事長兼執行長 Dave Zapico;執行副總裁兼財務長 Bill Burke;以及營運財務資深副總裁 Dalip Puri。

  • During the course of today's call, we will make forward-looking statements, which are subject to change based on various risk factors and uncertainties that may cause actual results to differ significantly from expectations. A detailed discussion of the risks and uncertainties that may affect our future results is contained in AMETEK's filings with the SEC. AMETEK disclaims any intention or obligation to update or revise any forward-looking statements.

    在今天的電話會議過程中,我們將發表前瞻性陳述;此類陳述可能因各種風險因素與不確定性而有所變動,並可能導致實際結果與預期有重大差異。可能影響我們未來業績之風險與不確定性的詳細討論,載於 AMETEK 向美國證券交易委員會(SEC)提交的文件中。AMETEK 不承擔更新或修訂任何前瞻性陳述之任何意圖或義務。

  • Any references made on this call to 2022 or 2023 results or to 2024 guidance will be on an adjusted basis, excluding after tax, acquisition-related intangible amortization Reconciliations between GAAP and adjusted measures can be found in our press release and on the Investors section of our website. We'll begin today's call with prepared remarks, and then we'll open it up for questions.

    本次電話會議中提及的 2022 或 2023 年結果,或 2024 年指引,均以調整後基礎呈現,排除稅後之併購相關無形資產攤銷。GAAP 與調整後衡量指標之間的調節表可見於我們的新聞稿以及公司網站的投資人專區。我們將先進行準備好的發言,之後開放提問。

  • I'll now turn the meeting over to Dave.

    現在我把會議交給 Dave。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Thank you, Kevin, and good morning, everyone. Before I get into the financial results for the quarter, it is with mixed emotions that I share the news of changes in our financial leadership, which we announced on January 16.

    謝謝你,Kevin,各位早安。在我談到本季財務結果之前,我懷著複雜的心情分享我們於 1 月 16 日宣布的財務領導團隊變動消息。

  • After an outstanding 36-year career at AMETEK, our Chief Financial Officer, Bill Burke, has decided to embark on a well-deserved retirement, effective April 2, 2024. Bill's tremendous leadership of our finance organization and his strategic guidance has been instrumental in AMETEK's long-term growth and success. His legacy is deeply woven into the fabric of our organization, and we express our heartfelt gratitude for his exceptional contributions.

    在 AMETEK 服務 36 年、成就卓越的職涯之後,我們的財務長 Bill Burke 決定展開當之無愧的退休生活,並將於 2024 年 4 月 2 日生效。Bill 對我們財務組織的卓越領導與策略指引,對 AMETEK 的長期成長與成功至關重要。他的傳承已深深融入我們組織的核心,我們對他非凡的貢獻致上由衷的感謝。

  • In light of this transition, I'm delighted to announce the appointment of Dalip Puri as our new Executive Vice President and Chief Financial Officer. Dalip, currently serving as Senior Vice President, Operational Finance, brings a wealth of experience and expertise to this role. Dalip joined AMETEK in 2017 as Treasurer and subsequently took on the role of Group Controller, providing financial oversight for over half of AMETEK's businesses before transitioning into his current role of Operational Finance.

    因應此次交接,我很高興宣布任命 Dalip Puri 擔任新的執行副總裁兼財務長。Dalip 目前擔任營運財務資深副總裁,將以豐富的經驗與專業勝任此職。Dalip 於 2017 年加入 AMETEK 擔任財務長(Treasurer),之後接任集團財務控管長(Group Controller),為 AMETEK 超過一半的業務提供財務監督,隨後轉任目前的營運財務職務。

  • Dalip's leadership of key financial initiatives at AMETEK, along with a proven track record make him the natural choice to lead our financial organization into the future. I'm confident that under Dalip's leadership, our financial organization will continue to thrive contributing significantly to the success of AMETEK. To ensure a seamless transition, Bill will stay on as a senior adviser until April 2025. Thank you, Bill, for your exceptional service, and congratulations Dalip. I'm truly excited about the future.

    Dalip 在 AMETEK 領導多項關鍵財務計畫,加上其經驗證的績效表現,使他成為帶領我們財務組織邁向未來的最佳人選。我相信在 Dalip 的領導下,我們的財務組織將持續蓬勃發展,並為 AMETEK 的成功做出重大貢獻。為確保順利交接,Bill 將以資深顧問身分留任至 2025 年 4 月。Bill,感謝你卓越的服務;也恭喜 Dalip。我對未來感到非常振奮。

  • Now let me turn to this quarter's results. AMETEK delivered exceptional performance in the fourth quarter, delivering record results and outstanding operational execution, leading to results ahead of our expectations. In the quarter, we set records for sales, operating income, earnings per share, EBITDA and cash flow. We also ended the quarter with record backlog.

    接下來談本季業績。AMETEK 在第四季展現卓越表現,創下紀錄性的成果並有出色的營運執行,使得結果優於我們的預期。本季我們在營收、營業利益、每股盈餘、EBITDA 與現金流皆創新高。我們也在季末以創紀錄的在手訂單(backlog)作收。

  • Furthermore, in the quarter, we successfully deployed over $2 billion on strategic acquisitions, enhancing our portfolio with the acquisitions of Amplifier Research and Paragon Medical. These results cap a record year for acquisitions and underscore the strength of the AMETEK growth model, the quality of our businesses and the success of our organic growth initiatives. AMETEK's continued success is also the result of the dedicated efforts of our global employees. I want to thank all AMETEK colleagues for your efforts and significant contributions in 2023.

    此外,本季我們成功投入超過 20 億美元進行策略性併購,透過收購 Amplifier Research 與 Paragon Medical 強化了我們的投資組合。這些成果為併購創紀錄的一年畫下句點,並凸顯 AMETEK 成長模式的強勁、我們業務的高品質,以及我們有機成長計畫的成功。AMETEK 的持續成功也來自全球員工的投入與努力。我想感謝所有 AMETEK 同仁在 2023 年的付出與重大貢獻。

  • Now let me turn to our fourth quarter financial results. Fourth quarter sales were a record $1.73 billion, up 6.5% over the same period in 2022. Organic sales growth was approximately 1.5%. Acquisitions added 4 points and foreign currency added 1 point. We ended the quarter with a record backlog of $3.53 billion, which is up 10% from the start of 2023. AMETEK's operational performance in the quarter was outstanding, with robust margin expansion and strong incremental margins.

    接下來說明第四季財務結果。第四季營收創紀錄達 17.3 億美元,較 2022 年同期成長 6.5%。有機營收成長約 1.5%。併購貢獻 4 個百分點,外匯貢獻 1 個百分點。我們在季末的在手訂單創紀錄達 35.3 億美元,較 2023 年初增加 10%。AMETEK 本季營運表現非常出色,利潤率顯著擴張,增量利潤率也很強勁。

  • Operating income in the quarter was a record $445 million, a 12% increase over the fourth quarter of 2022. Operating margins were 25.7% in the quarter, up an impressive 120 basis points from the prior year, while core margins were up 200 basis points in the quarter. This strong margin expansion reflects the strength and flexibility of our operating model and the quality and differentiation of our businesses.

    本季營業利益創紀錄達 4.45 億美元,較 2022 年第四季成長 12%。本季營業利益率為 25.7%,較去年同期大幅提升 120 個基點;核心利潤率本季提升 200 個基點。這樣強勁的利潤率擴張反映了我們營運模式的強度與彈性,以及我們業務的品質與差異化。

  • EBITDA in the quarter was a record $526 million, up 8% over the prior year, with EBITDA margins an impressive 30.4%. Our strong growth and operating performance led to robust cash generation with free cash flow up 47% in the quarter to a record $481 million. This tremendous operating performance led to record diluted earnings per share of $1.68, up 11% versus the fourth quarter of 2022 and above our guidance range of $1.61 to $1.63 per share.

    本季 EBITDA 創紀錄達 5.26 億美元,較去年同期成長 8%,EBITDA 利潤率達到亮眼的 30.4%。強勁的成長與營運表現帶動穩健的現金創造能力,本季自由現金流年增 47% 至創紀錄的 4.81 億美元。這樣卓越的營運表現帶動稀釋後每股盈餘創紀錄達 1.68 美元,較 2022 年第四季成長 11%,並高於我們每股 1.61 至 1.63 美元的指引區間。

  • Now let me provide some additional details at the operating group level. First, the Electronic Instruments Group. The Electronic Instruments Group had an excellent quarter with strong sales growth and tremendous operating performance. Sales for EIG were a record $1.24 billion in the quarter, up 7% from the fourth quarter of last year. Organic sales were up 3.5%, acquisitions added 3 points with currency accounting for the balance. EIG sales growth in the fourth quarter was strongest across our Aerospace & Defense businesses and our Materials Analysis division.

    接下來提供營運事業群層級的更多細節。首先是電子儀器事業群(Electronic Instruments Group,EIG)。EIG 本季表現優異,營收成長強勁,營運表現也非常出色。EIG 本季營收創紀錄達 12.4 億美元,較去年第四季成長 7%。有機營收成長 3.5%,併購貢獻 3 個百分點,其餘為匯率因素。EIG 第四季的營收成長主要來自航太與國防業務,以及材料分析事業部。

  • EIG's operating performance was impressive with strong profit growth and exceptional margin expansion. Operating income was a record $359 million, up 17% versus the prior year, while EIG operating margins were 29%, up and outstanding 250 basis points from the prior year. The Electromechanical Group also finished the year with strong performance despite the continued impact from the normalization of inventory levels across our OEM customer base.

    EIG 的營運表現令人印象深刻,獲利成長強勁且利潤率擴張卓越。營業利益創紀錄達 3.59 億美元,較去年同期成長 17%;EIG 營業利益率為 29%,較去年同期大幅提升 250 個基點。機電事業群(Electromechanical Group,EMG)在 OEM 客戶端庫存水位持續正常化的影響下,仍以強勁表現為全年畫下句點。

  • Fourth quarter sales for EMG were $495 million, up 6% versus the prior year, driven by the contributions from recent acquisitions. EMG's fourth quarter operating income was $112 million, while operating margin -- operating income margins were 22.7% in the quarter. Excluding the dilutive impact from acquisitions, EMG core margins were up 100 basis points versus the prior year.

    EMG 第四季營收為 4.95 億美元,較去年同期成長 6%,主要由近期併購的貢獻所帶動。EMG 第四季營業利益為 1.12 億美元,營業利益率為 22.7%。若排除併購帶來的稀釋影響,EMG 核心利潤率較去年同期提升 100 個基點。

  • Now for the full year results. Overall performance was outstanding in 2023, establishing annual records for essentially all key financial metrics. Overall sales for the year were $6.6 billion, up 7% from 2022. Organic sales increased 4%, with acquisitions accounting for the balance of the growth. Operating income for 2023 was $1.7 billion, up 14% and operating margins were 25.9% for the full year, with margins up 150 basis points versus the prior year.

    接下來是全年結果。2023 年整體表現非常出色,幾乎所有關鍵財務指標皆創下年度紀錄。全年總營收為 66 億美元,較 2022 年成長 7%。有機營收成長 4%,其餘成長由併購貢獻。2023 年營業利益為 17 億美元,成長 14%;全年營業利益率為 25.9%,較去年提升 150 個基點。

  • EBITDA for the year was $2 billion with EBITDA margins are very strong, 30.5%. In full year 2023, earnings were $6.38 per diluted share, up 12% versus the prior year. Our performance in the fourth quarter and full year highlights the strength of the AMETEK growth model. Our differentiated businesses are strategically aligned with diverse and attractive markets, while our organic growth initiatives position us for sustained long-term growth.

    全年 EBITDA 為 20 億美元,EBITDA 利潤率非常強勁,達 30.5%。2023 年全年稀釋後每股盈餘為 6.38 美元,較去年成長 12%。我們在第四季與全年的表現凸顯 AMETEK 成長模式的強勁。我們具差異化的業務在策略上與多元且具吸引力的市場相契合,而我們的有機成長計畫也使我們具備長期、可持續的成長動能。

  • Our distributed operating structure empowers our businesses to execute on our growth strategies and quickly adapt to evolving market dynamics. This structure is a cornerstone of the success and navigating throughout different economic cycles. Furthermore, our asset-light business model and strong operational execution result in exceptional cash flow generation. This robust cash flow, coupled with our strong balance sheet, provides AMETEK with plenty of firepower to support our growth initiatives and to deploy on acquisitions.

    我們分散式的營運架構使各事業能夠落實成長策略,並快速因應不斷變化的市場動態。此一架構是我們成功的基石,也有助於我們在不同經濟循環中穩健前行。此外,我們的輕資產商業模式與強勁的營運執行,帶來卓越的現金流創造能力。這股強勁現金流,加上我們穩健的資產負債表,為 AMETEK 提供充足火力以支持成長計畫並投入併購。

  • Speaking of acquisitions, we were very active in 2023, successfully deploying approximately $2.25 billion on 5 acquisitions, including the acquisitions of Amplifier Research and Paragon Medical in the fourth quarter. I'm very excited to welcome all acquired companies to AMETEK. Each acquisition is an excellent strategic fit with AMETEK as they help expand our product and technology offerings and highly attractive growth markets and applications, including renewable energy development and the modernization of the Power group.

    談到併購,我們在 2023 年非常積極,成功投入約 22.5 億美元完成 5 項併購,其中包括第四季收購 Amplifier Research 與 Paragon Medical。我非常高興歡迎所有被收購公司加入 AMETEK。每一項併購都與 AMETEK 的策略高度契合,因為它們有助於擴大我們的產品與技術供給,並切入極具吸引力的成長市場與應用領域,包括再生能源發展以及電力事業群的現代化。

  • In addition, our latest acquisition, Paragon Medical, which we closed in the middle of December, nicely expands our presence in the medical technology market. Paragon is a leading manufacturer specializing in highly engineered medical components and single-use and consumable surgical instruments. Their product portfolio spans crucial medical applications, and the reputation for quality and precision has earned them the trust of a diverse customer base, including top-tier medical device OEMs.

    此外,我們最新的收購案 Paragon Medical 已於 12 月中旬完成交割,進一步擴大了我們在醫療科技市場的布局。Paragon 是領先的製造商,專精於高工程化醫療零組件,以及一次性與耗材型手術器械。其產品組合涵蓋關鍵醫療應用領域,並以品質與精密度著稱,因而贏得多元客戶群的信賴,其中包括頂尖醫療器材 OEM。

  • Looking ahead to 2024. Our acquisition pipeline remains robust. As noted, we have a strong and flexible balance sheet and anticipate remaining active deploying capital and acquisitions. In addition to our acquisition strategy, AMETEK remains committed to making strategic investments in organic growth initiatives. In 2023, we invested an incremental $100 million in growth initiatives. And in 2024, we expect to invest another incremental $100 million. The majority of this investment will be within our research, development and engineering and sales and marketing functions.

    展望 2024 年,我們的併購案源仍然強勁。如前所述,我們擁有強健且具彈性的資產負債表,預期將持續積極投入資本並進行併購。除併購策略外,AMETEK 亦持續致力於在內生成長計畫上進行策略性投資。2023 年,我們在成長計畫上額外投入 1 億美元;而在 2024 年,我們預期將再額外投入 1 億美元。此投資的大部分將用於我們的研發與工程,以及銷售與行銷等職能。

  • In the quarter, our vitality index, which reflects sales from new products introduced in the last 3 years was a very healthy 29%. Through these strategic investments and acquisitions, we have seen a steady transition of AMETEK's portfolio, with an expanded presence in secular growth markets and reduced exposures in more cyclical markets. This strategic evolution of the portfolio, combined with our proven operational acumen, positions AMETEK well for continued strong and sustained growth.

    本季,我們的活力指數(反映過去 3 年內推出之新產品所帶來的銷售)維持在非常健康的 29%。透過這些策略性投資與併購,我們看到 AMETEK 的產品組合持續穩健轉型,在長期結構性成長市場的布局擴大,同時降低對較具循環性的市場曝險。此一產品組合的策略性演進,加上我們經驗證的卓越營運能力,使 AMETEK 具備持續強勁且可延續成長的良好條件。

  • Now shifting to our outlook for the year ahead. For 2024, we expect overall sales to be up low double digits on a percentage basis with low to mid-single-digit organic sales growth. Diluted earnings per share for the year are expected to be in the range of $6 to $6.85, up 5% to 7% compared to last year's results. For the first quarter, we anticipate overall sales to be up low double digits with adjusted earnings of $1.56 to $1.60 per share, up 5% to 7% versus the prior year.

    接著談談我們對未來一年的展望。2024 年,我們預期整體銷售額以百分比計將呈現低雙位數成長,其中有機銷售成長為低至中個位數。全年稀釋每股盈餘預期介於 6.00 美元至 6.85 美元,較去年結果成長 5% 至 7%。第一季方面,我們預期整體銷售額同樣為低雙位數成長,調整後每股盈餘為 1.56 美元至 1.60 美元,較去年同期成長 5% 至 7%。

  • In summary, AMETEK's performance in the fourth quarter and throughout the full year of 2023 was outstanding. Our businesses delivered exceptional results with all elements of the AMETEK growth model, playing a key role in our success.

    總結而言,AMETEK 在第四季以及 2023 全年的表現都非常出色。我們各事業單位交出卓越成果,AMETEK 成長模式的各項要素也都在成功中扮演關鍵角色。

  • I will now turn it over to Bill Burke, who will cover some of the financial details of the quarter, and then we'll be glad to take your questions. Bill?

    接下來我把時間交給 Bill Burke,他將說明本季的一些財務細節,之後我們很樂意回答各位的問題。Bill?

  • William Joseph Burke - Executive VP & CFO

    William Joseph Burke - Executive VP & CFO

  • Thank you, Dave. I appreciate your kind words at the top of the call. As Dave noted, I have made the decision to retire after 36 years with AMETEK, nearly 8 of which I had the privilege of serving as Chief Financial Officer. I want to express my deepest gratitude and thanks to the entire AMETEK family for the incredible journey we've shared. It has been an honor to contribute to the tremendous growth and success of AMETEK.

    謝謝你,Dave。我很感謝你在電話會議一開始對我的肯定。如 Dave 所提,我已決定在 AMETEK 服務 36 年後退休,其中近 8 年有幸擔任財務長。我想向整個 AMETEK 大家庭表達最深的感激與謝意,感謝我們共同走過這段精彩旅程。能為 AMETEK 的巨大成長與成功做出貢獻,是我的榮幸。

  • To Dave and the Board of Directors, thank you for your confidence in me. Your support and leadership have been invaluable. And to my colleagues, your dedication has been the driving force behind our share of success, and I am truly thankful for the privilege of working closely with you. I look forward to remaining with the company as a senior adviser until April 2025 to ensure a seamless transition. I'm confident in Dalip's leadership and in the very strong and talented financial organization at AMETEK.

    也要謝謝 Dave 與董事會對我的信任,你們的支持與領導一直都非常寶貴。並且對我的同仁們,你們的投入是推動我們成功的動力,我也真心感謝能有機會與各位密切合作。我期待在 2025 年 4 月前以資深顧問身分留任,以確保順利交接。我對 Dalip 的領導能力,以及 AMETEK 非常強大且人才濟濟的財務組織充滿信心。

  • Before I get into the results for the fourth quarter, Dalip would like to say a few words. Dalip?

    在我進入第四季業績之前,Dalip 想先說幾句話。Dalip?

  • Dalip Mohan Puri - SVP of Operational Finance

    Dalip Mohan Puri - SVP of Operational Finance

  • Thank you, Bill, and good morning, everyone. I look forward to meeting and working with all of you in the new future. I too want to express my thanks to Dave, to Bill, to the Board of Directors and the leadership team for their trust and confidence in me. It is an honor to serve as AMETEK's EVP and CFO, and I'm very excited to lead AMETEK's incredible finance organization and to partner with Dave as we continue to deliver sustained and strong growth across our portfolio of businesses. I also want to express my thanks to Bill for his guidance and mentorship over the years and his commitment to a smooth transition.

    謝謝你,Bill,各位早安。我期待在新的未來與各位見面並一起合作。我也想向 Dave、Bill、董事會以及領導團隊表達謝意,感謝你們對我的信任與肯定。能擔任 AMETEK 的執行副總裁暨財務長,我深感榮幸,也非常期待帶領 AMETEK 卓越的財務團隊,並與 Dave 攜手,持續在我們的事業組合中交出穩健且強勁的成長。我也要感謝 Bill 多年來的指導與提攜,以及他對順利交接的承諾。

  • With that, I'll turn it back to you, Bill.

    接著我把時間交回給你,Bill。

  • William Joseph Burke - Executive VP & CFO

    William Joseph Burke - Executive VP & CFO

  • Thank you, Dalip. Now on to the fourth quarter results. As Dave highlighted, AMETEK had an impressive finish to 2023 with outstanding operating performance leading to better-than-expected results in the fourth quarter. Let me provide some additional financial highlights for the fourth quarter and the full year as well as some additional guidance for 2024.

    謝謝你,Dalip。接下來談第四季業績。如 Dave 所強調,AMETEK 在 2023 年收官表現亮眼,卓越的營運績效帶動第四季結果優於預期。我將補充一些第四季與全年財務重點,並提供 2024 年的進一步指引。

  • Fourth quarter general and administrative expenses were $26.3 million, up $3 million from the prior year, but unchanged at 1.5% of sales. For the full year, general and administrative expenses were up $7 million and as a percentage of sales were 1.5%, in line with 2022 levels. For 2024, general and administrative expenses are expected to be approximately 1.4% of sales. Fourth quarter other income and expense was additional expense of $7 million compared to the fourth quarter of 2022, driven by higher due diligence costs and lower pension income.

    第四季一般及行政費用為 2,630 萬美元,較去年增加 300 萬美元,但占銷售額比重維持不變,為 1.5%。全年一般及行政費用增加 700 萬美元,占銷售額比重為 1.5%,與 2022 年水準一致。2024 年,一般及行政費用預期約占銷售額 1.4%。第四季其他收益與費用為額外費用 700 萬美元,較 2022 年第四季增加,主要因盡職調查成本較高以及退休金收入較低所致。

  • For 2024, we expect other income and expense to be largely in line with 2023 levels. The effective tax rate in the quarter was 17.8%, down from 18.9% in the fourth quarter of 2023 due to statute expirations. For 2024, we anticipate our effective tax rate to be between 19% and 20%. And as we've stated in the past, actual quarterly tax rates can differ dramatically, either positively or negatively from this full year estimated rate.

    2024 年,我們預期其他收益與費用大致與 2023 年水準相當。本季有效稅率為 17.8%,較 2023 年第四季的 18.9% 下降,主要因法規條款到期所致。2024 年,我們預期有效稅率介於 19% 至 20%。如同我們過去所述,實際的季度稅率可能相較於全年估計稅率出現顯著差異,可能高於或低於該水準。

  • Capital expenditures were $60 million in the fourth quarter and $136 million for the full year. Capital expenditures in 2024 are expected to be approximately $160 million or about 2% of sales. Depreciation and amortization expense in the quarter was $92 million and for the full year was $338 million. 2024, we expect depreciation and amortization to be approximately $400 million, including after-tax, acquisition-related intangible amortization of approximately $190 million or $0.82 per diluted share.

    第四季資本支出為 6,000 萬美元,全年為 1.36 億美元。2024 年資本支出預期約為 1.6 億美元,約占銷售額 2%。本季折舊與攤銷費用為 9,200 萬美元,全年為 3.38 億美元。2024 年,我們預期折舊與攤銷約為 4 億美元,其中包含稅後、與併購相關之無形資產攤銷約 1.9 億美元,或每股稀釋 0.82 美元。

  • For the quarter, operating working capital was 17.2% of sales. Cash flow in the fourth quarter was superb with operating cash flow of record at $541 million, up 40% versus the fourth quarter of 2022. Free cash flow was also a record in the quarter, up 47% to $481 million, with free cash flow conversion of 140% for the quarter. Free cash flow for 2023 was $1.6 billion, up 58% versus the prior year and 122% of net income. For 2024, we expect free cash flow conversion to be between 110% and 120% of net income.

    本季營運周轉資金占銷售額比重為 17.2%。第四季現金流表現極佳,營運現金流創下 5.41 億美元的紀錄,較 2022 年第四季成長 40%。本季自由現金流亦創新高,成長 47% 至 4.81 億美元,自由現金流轉換率為 140%。2023 年自由現金流為 16 億美元,較前一年成長 58%,相當於淨利的 122%。2024 年,我們預期自由現金流轉換率將介於淨利的 110% 至 120%。

  • Total debt at year-end was $3.31 billion, up from $2.39 billion at the end of 2022 due largely to the Paragon acquisition in December. Offsetting this debt is cash and cash equivalents of $410 million. As Dave noted, during the fourth quarter, we deployed approximately $2 billion on the acquisitions of Amplifier Research and Paragon Medical. Our gross leverage was 1.5x at the end of 2023, up from 1.2x at the end of 2022, despite deploying approximately $2.25 billion on acquisitions during the year. We remain very well positioned to deploy additional capital and have approximately $1.5 billion of cash and existing credit facilities to support our growth initiatives.

    年底總負債為 33.1 億美元,較 2022 年底的 23.9 億美元增加,主要因 12 月完成 Paragon 收購所致。與此負債相對應的是 4.10 億美元的現金及約當現金。如 Dave 所述,第四季我們在 Amplifier Research 與 Paragon Medical 的收購上合計投入約 20 億美元。2023 年底我們的總槓桿倍數為 1.5 倍,高於 2022 年底的 1.2 倍,儘管全年在併購上投入約 22.5 億美元。我們仍具備非常良好的條件以部署更多資本,並擁有約 15 億美元的現金與既有授信額度,以支持我們的成長計畫。

  • In summary, our businesses performed exceptionally well in the fourth quarter and throughout all of 2023, delivering strong growth and a high quality of earnings. We are well positioned for continued growth and success in 2024.

    總結而言,我們的事業在第四季以及 2023 全年表現都非常出色,帶來強勁成長與高品質的獲利。我們已為 2024 年持續成長與成功做好充分準備。

  • Thank you once again, and now I'll turn it back to Kevin.

    再次謝謝各位,接下來我把時間交回給 Kevin。

  • Kevin C. Coleman - VP of IR & Treasurer

    Kevin C. Coleman - VP of IR & Treasurer

  • Great. Thank you, Bill. Tanya, can we please open the line for questions?

    好的,謝謝你,Bill。Tanya,麻煩可以開放電話線讓大家提問嗎?

  • Operator

    Operator

  • (Operator Instructions) And our first question will come from Matt Summerville of D.A. Davidson.

    (接線員指示)我們的第一個問題來自 D.A. Davidson 的 Matt Summerville。

  • Matt J. Summerville - MD & Senior Research Analyst

    Matt J. Summerville - MD & Senior Research Analyst

  • Congrats, Bill. I wanted to first ask about the EMG business and the inventory normalization you're seeing there. Using a baseball analogy, what inning are we in with respect to that normalization? And when do you start to see inflection in organic orders within EMG. So if you can first maybe start by elaborating there? And then I have a follow-up.

    恭喜你,Bill。我想先問 EMG 事業以及你們在那裡看到的庫存正常化進展。用棒球作比喻,就庫存正常化而言,我們現在進行到第幾局了?另外,EMG 的有機訂單何時會開始出現拐點、轉為改善?如果可以的話,能否先就這部分再多做一些說明?然後我還有一個追問。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Sure. Sure, Matt. Maybe the first thing I want to do is, in the outlook for 2024, Kevin told me that it may have not come through clearly. The diluted EPS for the year is $6.70 to $6.85. So that's just maybe a correction of what I had said before, if it didn't come through clearly. And now I'll get to your question, Matt.

    當然。當然,Matt。也許我想先做的第一件事是,在 2024 年的展望上,Kevin 告訴我,這點可能沒有表達得很清楚。今年的稀釋後 EPS 為 6.70 美元到 6.85 美元。所以如果我先前說的沒有清楚傳達,這算是一個更正。現在我來回答你的問題,Matt。

  • I mean we think that, as we talked about the OEM parts of our business and we think that OEM destocking largely played out as we expected during Q4, we expect it to continue through the first half of the year. We're going to have some difficult comps in Q1, then it will finish in Q2, and then we're going -- we're pretty good for the second half of the year, the way we're forecasting. So the -- again, we're working off our backlog right now. So it's not an immediate impact on revenue. But that destock will continue for the first half of the year, probably a bit more in Q1 than Q2, but we think will be good for the second half of the year. And it's already starting to happen. Some customers are have corrected their inventory levels, but it will continue through the first half of the year.

    我的意思是,我們認為,正如我們談到業務中的 OEM 部分一樣,我們認為 OEM 去庫存基本上在第四季已如我們預期地進行,我們預期它會延續到上半年。我們在第一季會有一些比較基期的壓力,然後在第二季結束,接著我們——依照我們的預測——下半年會相當不錯。所以——再次強調——我們目前是在消化積壓訂單。因此對營收不是立即性的影響。但去庫存會在上半年持續,第一季可能比第二季更明顯一些,但我們認為下半年會比較好。而且這已經開始發生了。有些客戶已修正其庫存水位,但這個過程仍會延續到上半年。

  • Matt J. Summerville - MD & Senior Research Analyst

    Matt J. Summerville - MD & Senior Research Analyst

  • Got it. And then can you review what you experienced in terms of price capture in '23 over '22, and what we should be thinking about in '24. And ultimately, what that price cost relationship looks like this year?

    了解。那接著你能否回顧一下,你們在 23 年相較 22 年的價格取得(price capture)表現如何,以及我們在 24 年應該怎麼看?最終,今年的價格與成本之間的關係會是什麼樣子?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes, sure. In the fourth quarter, price was about 5% of sales. And total inflation was about 3.5%. And when we transition to 2024, we really see inflation decreasing. So the time where we had very significant price increases to be at or above inflation is coming to an end. And we think pricing in 2024 would be about 3% across the entire portfolio, and we think inflation will be at about 2.5%. And so we maintain a positive spread. We have the product differentiation. We're creating value. You see our new products are selling very well. But we budgeted, I would say, conservatively at 3% price capture during 2024.

    是的,當然。第四季,價格因素約占銷售額的 5%。而總通膨約為 3.5%。當我們轉向 2024 年時,我們確實看到通膨在下降。因此,過去那段為了追上或高於通膨而進行非常顯著漲價的時期正接近尾聲。我們認為 2024 年整體產品組合的定價大約是 3%,而我們認為通膨大約在 2.5%。因此我們維持正向的價差。我們有產品差異化,正在創造價值。你也看到我們的新產品銷售得非常好。但我會說,我們在 2024 年以 3% 的價格取得做了相對保守的預算。

  • Operator

    Operator

  • (Operator Instructions) Our next question will be coming from Deane Dray of RBC Capital Markets.

    (接線員指示)下一個問題來自 RBC Capital Markets 的 Deane Dray。

  • Deane Michael Dray - MD of Multi-Industry & Electrical Equipment & Analyst

    Deane Michael Dray - MD of Multi-Industry & Electrical Equipment & Analyst

  • Just I'd like to add my congrats to Bill and Dalip. And Bill that is just the epitome of a distinguished career. So congratulations, and you'll be missed.

    我想先向 Bill 和 Dalip 表達祝賀。Bill,你的職涯真的是傑出職涯的典範。恭喜你,你會讓人想念的。

  • William Joseph Burke - Executive VP & CFO

    William Joseph Burke - Executive VP & CFO

  • I appreciate that, Deane. Thank you very much.

    我很感謝,Deane。非常謝謝你。

  • Deane Michael Dray - MD of Multi-Industry & Electrical Equipment & Analyst

    Deane Michael Dray - MD of Multi-Industry & Electrical Equipment & Analyst

  • Dave, maybe you can take us through the key end markets and what you're seeing in terms of demand orders. And then what does Paragon do in terms of increasing your percent of medical? Is that in the range that you're comfortable with? And how do you expect to grow it from there?

    Dave,也許你可以帶我們看一下主要終端市場,以及你在需求訂單方面看到的情況。然後 Paragon 在提高你們醫療占比方面做了什麼?這個占比落在你們覺得舒適的區間嗎?你們預期接下來要如何成長?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes, I'll start with that. With the Paragon acquisition, our portfolio has about 21% of sales into the med tech space. And we like to see that even larger. So we're still looking for acquisition in that space, and we plan to grow nicely within that space. And in fact, in the fourth quarter, Q4, we were up mid-single digits with strong growth on our EMC and Rauland businesses before we got Paragon integrated. So we're happy with the space. We want to continue to grow it, and we're still looking for deals in the space.

    是的,我先從這點開始。透過收購 Paragon,我們的產品組合約有 21% 的銷售進入醫療科技(med tech)領域。我們希望這個比重能更高。因此我們仍在尋找該領域的併購機會,也計畫在該領域內有不錯的內生成長。事實上,在第四季 Q4,在我們把 Paragon 整合進來之前,我們的 EMC 與 Rauland 業務就以強勁成長帶動,達到中個位數成長。所以我們對這個領域很滿意。我們想持續擴大,也仍在尋找該領域的交易機會。

  • Now I'll go around the horn, per se, I look at our various subsegments and end markets, and I'll start with our Process businesses, which are the largest component of our subsegments. And organic sales for Process were up low single digits in the quarter, completing a strong year that saw a broad-based growth across the segment.

    接著我就逐一說明,我看看我們各個次分部與終端市場。我先從我們的 Process 業務開始,這是我們次分部中最大的組成。Process 的有機銷售在本季為低個位數成長,為一個強勁年度畫下句點,該年度在整個部門呈現廣泛的成長。

  • Growth was strongest within our CAMECA and Zygo businesses given their strong technology positions with attractive research, optics and medical applications. We look to 2024, we expect organic sales for the Process businesses to be up low single digits for the full year. So it's a low single digits in 2023, low single digits in 2024. Aerospace & Defense, strong fourth quarter to complete an excellent year. Growth was broad-based across all segments. Organic growth was up high single digits in the quarter. The growth was balanced across our commercial and aerospace businesses. And for 2024, we expect the organic sales of the Aerospace & Defense businesses to again be up high single digits with similar growth across commercial aerospace and defense.

    成長最強的是我們的 CAMECA 與 Zygo 業務,因為它們在技術上具備強勢地位,並且在研究、光學與醫療應用方面具有吸引力。展望 2024 年,我們預期 Process 業務全年有機銷售將為低個位數成長。所以 2023 年是低個位數,2024 年也是低個位數。航太與國防方面,第四季表現強勁,為一個極佳年度收尾。成長在所有部門都很廣泛。本季有機成長為高個位數。成長在我們的商用與航太業務之間相當均衡。至於 2024 年,我們預期航太與國防業務的有機銷售將再次達到高個位數成長,且商用航太與國防的成長幅度相近。

  • I'll move to our Power businesses. They were up low double digits in the fourth quarter with contributions from the acquisitions of RTDS, UEI and Amplifier Research being offset by low single-digit organic sales growth. Our power businesses have been very active on the acquisition front with 3 highly strategic acquisitions over the past 15 months. These acquisitions broaden our exposure to attractive applications tied to renewable energy and modernization of the power grid. For 2024, we expect organic sales for the Power & Industrial businesses to be up low to mid-single digits. So there's some project -- that business is more impacted by certain projects, and we feel pretty good that we're going to be able to grow low to mid-single digits in 2024, some positive project evolutions.

    接著我談我們的 Power 業務。第四季成長為低雙位數,其中 RTDS、UEI 與 Amplifier Research 的併購貢獻,被低個位數的有機銷售成長所抵銷。我們的電力業務在併購方面非常積極,過去 15 個月完成了 3 項高度策略性的收購。這些收購擴大了我們在具吸引力的應用上的曝險,這些應用與再生能源以及電網現代化相關。對 2024 年,我們預期 Power & Industrial 業務的有機銷售將為低到中個位數成長。這裡有一些專案——該業務較受特定專案影響——我們相當有信心 2024 年能達到低到中個位數成長,並且有一些正向的專案進展。

  • And then finally, our Automation & Engineered Solutions. The segment was up mid-single digits in the quarter, with contributions from the acquisitions of Paragon Medical and Bison Engineering, being offset by a mid-single-digit decrease in organic sales. Results were in line with expectations with the impact of the normalization of inventory levels that Matt asked about across our OEM customer base, and they really continued in the quarter as expected, and we expect them to continue into 2024.

    最後是我們的 Automation & Engineered Solutions。該部門本季為中個位數成長,其中 Paragon Medical 與 Bison Engineering 的併購貢獻,被有機銷售中個位數下滑所抵銷。結果符合預期,反映 Matt 所問到的、在我們 OEM 客戶群中庫存水位正常化的影響;這在本季如預期持續發生,我們也預期會延續到 2024 年。

  • In 2024, we expect the Automation & Engineered Solutions business to be up low single digits with stronger growth in the back half of the year as our customer base normalizes inventory levels than in the first half. So the second half for that sub-segment will be stronger growth than the first half. That's around the horn, Deane.

    在 2024 年,我們預期 Automation & Engineered Solutions 業務將為低個位數成長;隨著客戶群庫存水位在下半年趨於正常化,下半年的成長會比上半年更強。所以該次分部下半年會比上半年有更強的成長。以上就是逐一說明,Deane。

  • Deane Michael Dray - MD of Multi-Industry & Electrical Equipment & Analyst

    Deane Michael Dray - MD of Multi-Industry & Electrical Equipment & Analyst

  • That's fabulous. I appreciate it. And just it's remarkable how we're seeing that momentum from '23 carry into your expectations for '24. And just one quick follow-up on the $100 million in growth investments. How does that stack up in terms of the product categories? Is there anything -- is it skewed in one way or the other? Is it evenly distributed? And where does new product vitality go from here? You're 29% this quarter, your 26% last quarter. Is there a target in mind?

    太棒了。謝謝你的說明。而且很驚人的是,我們看到 23 年的動能延續到你們對 24 年的預期。再追問一個關於 1 億美元成長投資的問題。就產品類別而言,這筆投資的配置如何?有沒有——偏向某一類?還是平均分配?另外,新產品活力(new product vitality)接下來會怎麼走?你們本季是 29%,上季是 26%。有沒有一個目標?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. I think anywhere between 20% and 30% is a good number. So that's what we've always said. And when we started tracking this, it was back in the 15% range. So we certainly have made tremendous progress with our new product development efforts. In terms of where the $100 million comes from, it's really bottom up. So our business units put plans together. And if they want to go beyond what they invested in the prior year, we will pitch those plans in their budgeting and it's spread across the business. It goes at our best growth opportunities, and it's going to be about $100 million this year.

    是的。我認為 20% 到 30% 之間都是不錯的數字。這也是我們一直以來的說法。當我們開始追蹤這個指標時,大約在 15% 的區間。所以我們在新產品開發方面確實取得了巨大的進展。至於這 1 億美元的來源,基本上是自下而上。因此我們的事業單位會提出計畫。如果他們想要超過前一年投入的金額,我們會在預算編列時審視並支持這些計畫,而資金會分散在各個業務上。它會投向我們最好的成長機會,今年大約就是 1 億美元。

  • Operator

    Operator

  • Our next question will be coming from Allison Poliniak of Wells Fargo.

    下一個問題來自 Wells Fargo 的 Allison Poliniak。

  • Allison Ann Marie Poliniak-Cusic - Director & Senior Equity Analyst

    Allison Ann Marie Poliniak-Cusic - Director & Senior Equity Analyst

  • Congrats, Bill and look forward to working with you, Dalip. Just following on Deane's R&D question. The $100 million is incremental from the '23 that you did $100 million. As you push into this med tech space, does that number need to go up higher? I mean I'm just trying to think through the investment needed to continue those trajectories for those business...

    恭喜你,Bill,也期待與你共事,Dalip。延續 Deane 關於研發的問題。這 1 億美元相較於 23 年你們投入的 1 億美元是增量。當你們推進到這個醫療科技領域時,這個數字是否需要再提高?我的意思是,我只是想釐清,為了讓這些業務持續沿著這些軌跡成長,所需的投資會是什麼樣子……

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. We're currently investing just under 5.5% of sales on research, development and engineering. And as we buy higher technology businesses, that number will increase modestly. I think this year, we expect to spend $400 million on RD&E, which is up a good healthy double-digit amount on the total R&D spend.

    是的。我們目前在研發與工程(RD&E)上的投入略低於銷售額的 5.5%。隨著我們收購更高科技的企業,這個比例會小幅上升。我認為今年我們預期 RD&E 支出為 4 億美元,較總研發支出將增加一個健康的雙位數幅度。

  • So our R&D is a key part of our business. We have a lot of industrial technology products that we want to maintain leadership positions in. It allows us to get the pricing that we can get because we're providing unique value to our customers. I don't think you're going to see a big jump anywhere, but it's happening as we naturally evolve our portfolio to higher technology products.

    因此,我們的研發是業務的關鍵部分。我們有許多工業科技產品,希望維持其領導地位。這也讓我們能取得相應的定價,因為我們為客戶提供獨特的價值。我不認為你會看到任何地方出現大幅跳升,但隨著我們的產品組合自然演進到更高科技的產品,這種變化正在發生。

  • Allison Ann Marie Poliniak-Cusic - Director & Senior Equity Analyst

    Allison Ann Marie Poliniak-Cusic - Director & Senior Equity Analyst

  • Great. And just any color on M&A. You obviously had a record year last year, still in a good position from a leverage standpoint. What are you seeing or what are we expecting? I know you mentioned med tech is sort of a vertical you want to go into. Where are you seeing the greatest opportunities? Any difference in terms of size that we should be thinking through? Just any thoughts there.

    很好。再請教一下併購(M&A)的最新情況。你們去年顯然創下紀錄的一年,從槓桿角度看仍處於不錯的位置。你們目前看到什麼、或我們應該期待什麼?我知道你提到醫療科技(med tech)算是你們想切入的一個垂直領域。你們在哪些地方看到最大的機會?在交易規模方面,有沒有什麼差異是我們需要納入考量的?想聽聽你們的看法。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • No, I think we're looking at the more traditional size deals. And we're also -- we have a few of the larger size deals in our pipeline, and I would characterize Paragon on the outer edge of the larger size. We're very happy with the 5 deals that we got done. We deployed $2.25 billion. We did it across our business in different parts of it. They were high-quality additions. They expanded our presence in attractive growth markets. We have a very clear path to add value to these companies. Each business has a strong technology position. The deals will meet our traditional financial hurdles. Remember, it's a 10% return on invested capital in year 3.

    沒有,我認為我們主要還是在看較傳統規模的交易。同時——我們的管線裡也有幾筆較大規模的交易,我會把 Paragon 形容為偏向較大規模的外緣。我們對完成的 5 筆交易非常滿意。我們部署了 22.5 億美元,並且分散在公司不同業務板塊中進行。這些都是高品質的補強,擴大了我們在具吸引力的成長市場中的布局。我們有非常清晰的路徑可以為這些公司創造價值。每一個業務都有強勁的技術地位。這些交易也會符合我們一貫的財務門檻。請記得,我們的目標是在第 3 年達到 10% 的投入資本報酬率(ROIC)。

  • In terms of our pipeline, our pipeline remains very strong. And we are actively looking at a number of high-quality deals across a broad set of markets. As always, we'll remain disciplined when we do this. And I really think that we have the opportunity to differentiate our performance with the M&A element of our growth strategy, combined with our balance sheet and cash flow positions. I mean we excel when the markets are slowing or choppy because we had great OpEx and great M&A, and we see tremendous values in the market that we're tracking. The way the market is evolving, it's probably going to be 2, 3, 4 -- second quarter, third quarter, fourth quarter, with the bulk of the opportunities are. So -- but really, this year, the pipeline looks good, and we're optimistic.

    就我們的管線而言,目前仍然非常強勁。我們正積極評估多個高品質交易,涵蓋廣泛的市場。如同以往,我們會保持紀律來執行。我也確實認為,我們有機會透過成長策略中的併購要素,結合我們的資產負債表與現金流狀況,來做出差異化的表現。我的意思是,當市場放緩或波動時,我們往往表現更出色,因為我們有很好的營運費用(OpEx)管理與很好的併購,而我們也在追蹤的市場中看到非常可觀的價值。依市場演變來看,機會可能會落在第 2 季、第 3 季、第 4 季——主要的機會大多在那裡。所以——但總之,今年的管線看起來不錯,我們也很樂觀。

  • Operator

    Operator

  • (Operator Instructions) Our next question will be coming from Jeffrey Sprague. of Vertical Research.

    (接線員指示)下一個問題來自 Vertical Research 的 Jeffrey Sprague。

  • Jeffrey Todd Sprague - Founder & Managing Partner

    Jeffrey Todd Sprague - Founder & Managing Partner

  • Just on deals, Dave. I think on Paragon, you're expecting most or the accretion to really kick in, in 2025, not so much '24. But can you just give us a little color on what is the EPS impact embedded in your guide for Paragon in '24 and the other deals also?

    Dave,關於交易。我想就 Paragon 而言,你們預期大部分、或說增益(accretion)真正顯著的貢獻會在 2025 年開始,而不是 2024 年。但你能否再多提供一些資訊:在你們 2024 年的指引中,Paragon 對 EPS 的影響內含多少?以及其他交易也是?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Well, sure. Related to Paragon specifically, during the first half of the year, we're going to be doing some -- expect some muted growth for a couple of reasons. One, there is an inventory correction going on in the med tech market, and we're going to look at the portfolio and potentially prune some less product -- less profitable product areas.

    好的。就 Paragon 來說,在上半年我們會做一些——預期成長會比較溫和,原因有幾點。第一,醫療科技市場正在進行庫存修正;第二,我們會檢視產品組合,可能會修剪一些產品——一些獲利較低的產品領域。

  • So there's a whole process that we're going to go through during this first half. And -- but all that said, we're expecting the second half to be very strong because they got some new product introductions that are very exciting. But we continue to expect within our guidance is 8% to 10% accretion and in 2024. And this is back-end loaded as we leer in the integration costs.

    所以在上半年我們會走完一整套流程。不過——即便如此,我們預期下半年會非常強勁,因為他們有一些非常令人振奮的新產品推出。但在我們的指引中,我們仍預期 2024 年將帶來 8% 到 10% 的增益(accretion)。而且這會偏向下半年貢獻較多,因為我們會把整合成本納入考量。

  • Kevin C. Coleman - VP of IR & Treasurer

    Kevin C. Coleman - VP of IR & Treasurer

  • Does that clarify...

    這樣有釐清嗎……

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes, $0.08 to $0.10.

    有,0.08 到 0.10 美元。

  • Jeffrey Todd Sprague - Founder & Managing Partner

    Jeffrey Todd Sprague - Founder & Managing Partner

  • Yes, $0.08 to $0.10. Yes. And then just drilling a little bit further into some of the end markets, thanks for kind of going and doing it around the world. But kind of the semi-related markets in particular, which have kind of been the vein of a lot of people's existence here recently kind of looking for the bottom and the turn. Like what are you seeing in those markets? What do you see in the quarter specifically? And how does 2024 look?

    是的,0.08 到 0.10 美元。是的。那再稍微深入問一下部分終端市場,謝謝你剛才按全球來說明。不過特別是與半導體相關的市場,最近一直是很多人關注的焦點,大家都在找底部與反轉。你在那些市場看到什麼?就這一季而言你看到什麼?以及 2024 年看起來如何?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • We have a little different dynamic in semiconductor, and I talked about it on a couple of past calls because we have the memory downturn that a lot of people are seeing. We saw that too. But at the same time, we have some exceptional technology in our CAMECA business. It's a next-generation technology that's really is in demand in just about all fabs. And we also have our Zygo business. We're one of the few companies that can manufacture EUV, extreme ultraviolet optics and semiconductor fabrication.

    我們在半導體的動態有點不同,我在過去幾次電話會議也提過,因為很多人看到的記憶體下行,我們也看到了。但同時,我們在 CAMECA 業務有一些非常出色的技術。那是下一代技術,幾乎在所有晶圓廠(fabs)都很有需求。我們也有 Zygo 業務;我們是少數能夠製造 EUV(極紫外)光學元件並用於半導體製造的公司之一。

  • So those are 2 growing dynamics. It's a good place to be. They were able to offset some of the weakness we had in the -- I'll call it, the core memory part of the portfolio. And for 2023, we ended up 10%. So it was a growing market for us. And for 2024, we expect to additionally grow another plus mid-single digits. So largely because of the technology, we were able to grow in '23, and we think we'll continue to grow in '24.

    所以這是兩個成長動能,是個很好的位置。它們能夠抵消我們在——我稱之為產品組合中核心記憶體部分——所面臨的一些疲弱。2023 年我們最後成長了 10%,因此對我們而言那是個成長市場。2024 年我們預期還會再成長,幅度為正的中個位數。主要是因為技術因素,我們在 2023 年得以成長,也認為 2024 年會持續成長。

  • Operator

    Operator

  • Our next question will come from Nigel Coe of Wolfe Research.

    下一個問題來自 Wolfe Research 的 Nigel Coe。

  • Nigel Edward Coe - MD & Senior Research Analyst

    Nigel Edward Coe - MD & Senior Research Analyst

  • Bill, congratulations on your retirement. So just a few model [lines] for me for '24. The guidance for revenue growth of low double digits. I've got high single digits coming in from M&A, obviously, mainly Paragon. Is that the right kind of ballpark about 9% coming in from M&A, which implies sort of 2%, 3% organic. Is that the right level?

    Bill,恭喜你退休。那我這邊有幾個 2024 年模型上的問題。你們指引的營收成長是低雙位數。我估計併購帶來的是高個位數的貢獻,顯然主要是 Paragon。這樣的量級對嗎?大概 9% 來自併購,意味著有機成長大概 2%、3%。這樣的水準對嗎?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • You're in the ballpark, Nigel.

    你抓得差不多,Nigel。

  • Nigel Edward Coe - MD & Senior Research Analyst

    Nigel Edward Coe - MD & Senior Research Analyst

  • Okay. Great. That's helpful. And then just anything to call out on incremental margins across both segments. We're coming off some pretty tough comps in EIG. So just curious, how we should think about maybe overall margins, but more importantly, core incremental margins.

    好,很好,這很有幫助。那再問一下兩個部門的增量毛利率(incremental margins)有沒有什麼需要特別注意的?我們剛經歷 EIG 相當艱難的比較基期。所以想了解我們該如何看待整體毛利率,尤其是核心增量毛利率。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Are you talking about for 2024 or 2023?

    你是指 2024 還是 2023?

  • Nigel Edward Coe - MD & Senior Research Analyst

    Nigel Edward Coe - MD & Senior Research Analyst

  • 2024.

    2024。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • 2024?

    2024?

  • Nigel Edward Coe - MD & Senior Research Analyst

    Nigel Edward Coe - MD & Senior Research Analyst

  • Yes.

    是。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. I mean we had a fantastic margin year in 2023 and margins were up. Core margins were up 200 basis points in the fourth quarter, reported margins are up 120 basis points. EIG had a great quarter. EMG, it was dilutive because of acquisitions. And when you peel away what was going on, they're actually up 100 basis points. So really good margins, really good incrementals. And we think for 2024, they're going to moderate a bit. They're going to continue to grow them, but they're going to moderate a bit. And for 2024, we believe that core margins are going to be up 30 basis points. We think that the core incrementals are going to be up about 30 basis points.

    是的。我的意思是,我們在 2023 年的毛利率表現非常出色,毛利率是上升的。第四季核心毛利率上升 200 個基點,報告毛利率上升 120 個基點。EIG 有很棒的一季。EMG 因為併購而被稀釋(dilutive)。但如果把那些因素剝除,其實是上升 100 個基點。所以毛利率非常好、增量也非常好。我們認為 2024 年會稍微趨於溫和:仍會持續提升,但增幅會放緩。對 2024 年,我們認為核心毛利率將上升 30 個基點;核心增量也將約上升 30 個基點。

  • And we have built on our model cost reductions and pricing and things like that, but the whole thing that's to the core margins being up 30 and the core incremental is up 30 basis points. When you look at as reported margins for the year, those will be down probably about 50 basis points due to acquisition dilution. So that's the whole story.

    而且我們在模型中已納入成本降低、定價等因素;整體結論就是核心毛利率上升 30 個基點、核心增量上升 30 個基點。若看全年報告口徑(as reported)的毛利率,則可能會下降約 50 個基點,原因是併購稀釋。整體就是這樣。

  • Nigel Edward Coe - MD & Senior Research Analyst

    Nigel Edward Coe - MD & Senior Research Analyst

  • Okay. That's really helpful. And then just quickly on geographies. You've gone through the end markets, but just wondering if there's anything to call out in '24 geographically?

    了解,這很有幫助。那再快速問一下地區。你已經談過終端市場,但想請問 2024 年在地理區域上有沒有什麼需要特別指出的?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes, I'll do a summary of Q4 geographically, so you know where we stand. And we had growth in the quarter led by the U.S. and Asia. So the U.S. has been strong all along. Asia is picking up a bit. The U.S. was up mid-single digits with notable strength in our Materials Analysis division and Aerospace & Defense. Europe was down high single digits, driven in part by our automation business, and Asia was up about a little under 10%, about 9% with strength in our Materials Analysis division and our Ultra Precision Technology division.

    有,我先按地區總結一下第四季,讓你知道我們目前的狀況。本季成長主要由美國與亞洲帶動。美國一直以來都很強,亞洲也開始回升一些。美國成長中個位數,其中我們的材料分析(Materials Analysis)事業部以及航太與國防表現特別強。歐洲下滑高個位數,部分是由自動化業務所帶動;亞洲成長約略低於 10%,大概 9%,其中材料分析事業部與超精密技術(Ultra Precision Technology)事業部表現強勁。

  • We have a dynamic that was a little different than what's going on in the general marketplace. Our China sales were up 22% in Q4. So that -- they were up about 14%, 15% in the year, 22% in Q4. Strong growth in our Materials Analysis division and UPT. When we look into 2024, we think we'll grow in Asia, but we think China is going to moderate to more of a flattish market because there was some -- one of project businesses that we benefited from. So it's still going to be good for us, but we are seeing the broader impacts on the economy, and we think it will be flattish on an orders basis in 2024 in China, and we'll grow in Asia.

    我們有一個動態與整體市場有些不同。我們第四季在中國的銷售成長 22%。所以——全年大概成長 14%、15%,第四季成長 22%。材料分析事業部與 UPT 成長強勁。展望 2024 年,我們認為亞洲會成長,但中國會放緩到較接近持平的市場,因為我們先前受惠於某個專案型業務。因此對我們仍會是不錯的一年,但我們也看到更廣泛的經濟影響;我們認為 2024 年在中國的訂單基礎上會較為持平,而我們在亞洲會成長。

  • Operator

    Operator

  • Our next question will be coming from Scott Graham of Seaport Research Partners.

    下一個問題來自 Seaport Research Partners 的 Scott Graham。

  • Scott Graham - Senior Analyst

    Scott Graham - Senior Analyst

  • Bill, congratulations on a great run. It's been a complete pleasure working with you. I hope you remain happy invest to your family. Thank you.

    Bill,恭喜你有一段非常出色的任期。能與你共事完全是一種榮幸。我希望你能持續快樂,並把更多心力投入你的家庭。謝謝你。

  • William Joseph Burke - Executive VP & CFO

    William Joseph Burke - Executive VP & CFO

  • Thank you very much, Scott. Appreciate it.

    非常感謝你,Scott。感激不盡。

  • Scott Graham - Senior Analyst

    Scott Graham - Senior Analyst

  • I was hoping, Dave, you could go through the orders a bit for the quarter, both in total and organically?

    Dave,我想請你稍微談一下本季的訂單情況,包含總體以及有機成長的部分,可以嗎?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. Sure. The -- let me make sure I'm looking at the right stuff here. Yes. Yes, the orders in total for the quarter were up 16%. Now that was largely driven by the Paragon acquisition because the orders get booked as backlog the first when you acquire a business. So that 16% orders, EIG orders were up 3% and EMG orders were up 43%. And again, the EMG orders were driven by Paragon. Organically, the orders were minus 2%, and it translated into a book-to-bill of 1.10. Pretty much...

    可以。當然。這個——我先確認一下我看的是正確的資料。是的。是的,本季總訂單成長了16%。這主要是由 Paragon 併購所帶動,因為當你收購一家公司時,訂單會在第一時間以在手訂單(backlog)的形式入帳。所以這16%的訂單成長中,EIG 的訂單成長了3%,EMG 的訂單成長了43%。同樣地,EMG 的訂單是由 Paragon 所帶動。有機而言,訂單是-2%,換算成出貨對訂單比(book-to-bill)為1.10。大致上……

  • Scott Graham - Senior Analyst

    Scott Graham - Senior Analyst

  • And would you expect, Bill, that sometime in the first half, perhaps the second quarter that the orders may be really kind of flatten out for you organically and then start to progress into the second half?

    那 Bill,你是否預期在上半年某個時間點,也許是第二季,有機訂單可能會真正趨於持平,然後在下半年開始改善?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. I think in the first quarter, we have some pretty difficult comps. So I expect a similar trend with orders trailing sales. But then as we get out in the second half of the year, maybe even in the second quarter, I think the orders will outpace sales. Yes.

    是的。我認為第一季我們會遇到一些相當艱難的比較基期。所以我預期訂單落後於銷售的趨勢會類似。但當我們進入下半年,甚至可能在第二季,我認為訂單會跑贏銷售。是的。

  • Scott Graham - Senior Analyst

    Scott Graham - Senior Analyst

  • Got it. And then [Mike], just one other question. Within the guidance, I guess, I was a little bit surprised at the level of organic you're expecting in a good way. And it looks to me off of your summary that, that's stemming from the Aerospace & Defense businesses. Would you mind parsing out for the total company kind of what you're expecting in sort of Aerospace versus Defense this year and maybe tack on what the drivers are, particularly in commercial?

    了解。然後,[Mike],我還有一個問題。在你們的指引中,我想我對你們預期的有機成長水準有點驚訝——是好的那種驚訝。從你們的摘要看起來,這似乎是由航太與國防業務所帶動。你介意就整體公司層面,拆解一下今年你們對航太相對於國防各自的預期,以及驅動因素是什麼,特別是商用端?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. I mean the overall organic growth for the company is a low to mid-single-digit number, and that's going to be in both groups, EIG and EMG. And in terms of Aerospace, we think we're going to grow about the same level that we did this year at plus high single digits. And we have really good diversity in that business. And the military orders are strong, and the commercial OE aftermarket are strong, and the commercial OE are good, too. So we think largely the -- both the military and the total commercial markets are going to be up high single digits in 2024. Pretty optimistic about that.

    是的。公司的整體有機成長大約是低到中個位數,這會同時出現在兩個事業群:EIG 與 EMG。就航太而言,我們認為成長大概會與今年相近,約為高個位數的正成長。我們在該業務的多元性非常好。軍用訂單強勁,商用 OE 售後市場也強勁,商用 OE 也不錯。因此我們認為,2024 年軍用與整體商用市場大致都會是高個位數成長。我們對此相當樂觀。

  • Operator

    Operator

  • Our next question will come from Rob Wertheimer of Melius Research.

    下一個問題來自 Melius Research 的 Rob Wertheimer。

  • Robert Cameron Wertheimer - Founding Partner, Director of Research & Research Analyst

    Robert Cameron Wertheimer - Founding Partner, Director of Research & Research Analyst

  • So first question is just on growth into '24 and maybe even beyond on the growth algorithm. It seems like your expectations starting out the year is more price-led than volume. And I assume, obviously, some of the destock or channel that you talked about is holding that back. But as we get into 2H, are we looking at return to normal volume growth? And then maybe we're in place environment. I don't know if you have a bigger picture view on where pricing is going? Are we in more of a 3% world and as volume comes back, that kind of ticks up core as we exit the year? That's my first question.

    第一個問題是關於 2024 年、甚至更往後的成長邏輯(growth algorithm)。看起來你們年初的預期更偏向由價格帶動,而非由量帶動。我想你們提到的一些去庫存或通路因素,顯然正在壓抑它。但當我們進入下半年時,我們是否會看到回到正常的量成長?另外,也許是在定價環境方面,我不確定你們是否有更宏觀的看法:定價會走向哪裡?我們是否處在一個約3%的世界,而當量回來時,核心成長在年底退出時會因此上修?這是我的第一個問題。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. That very well could happen, Rob. I think the -- I think we're in a 3% pricing world. And I think our volume has the potential to be a little stronger in the second half than the first half. So that -- what you're saying is kind of how we're thinking about it. We've been pretty conservative in our second half outlook. But if there was something that could exceed it, it will be the second half volume. Sales volume organically.

    是的,Rob,這很有可能發生。我認為——我認為我們處在一個約3%的定價世界。而且我認為我們的量在下半年有可能比上半年更強。所以你所說的,基本上就是我們的思考方式。我們對下半年的展望一直相當保守。但如果有什麼可能超出預期,那會是下半年的量——有機的銷售量。

  • Robert Cameron Wertheimer - Founding Partner, Director of Research & Research Analyst

    Robert Cameron Wertheimer - Founding Partner, Director of Research & Research Analyst

  • Okay. Perfect. And then I wonder, just given the rise of med tech in the portfolio, if you could just give a general thoughts on your value add there. Is it different from anything in the core? General thoughts on core growth there. And then if the acquisition environment differs at all, if it's more white space, if it's more competing against others and deals? Just a couple of general thoughts there, if you would.

    好的,很好。接著我想問,鑑於醫療科技在你們投資組合中的比重上升,能否談談你們在那裡的價值增益(value add)?它和核心業務有什麼不同嗎?也請談談那裡的核心成長的一般看法。最後,併購環境是否也有所不同——例如是否有更多空白領域(white space)、是否更需要與其他競爭者搶案源與交易?想請你分享幾點一般性的看法。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes, we've been -- acquired some good medical businesses. I mean if we go back and look, the Rauland business has been a fabulous winner for us, and that business is growing in the market. And we made an EMC acquisition, and that business has been very successful. And that business is in the similar market that Paragon has been. So that gave us confidence. And it's -- they're classic AMETEK businesses. We win in the market based on technology, based on engineering. They're a little more OEM than end market.

    是的,我們收購了一些很好的醫療業務。我的意思是,如果回頭看,Rauland 業務對我們來說是非常出色的成功案例,而且該業務在市場中持續成長。我們也做了一筆 EMC 的收購,那個業務也非常成功。而那個業務所處的市場與 Paragon 類似,所以這給了我們信心。而且——它們是典型的 AMETEK 業務。我們在市場上取勝是靠技術、靠工程能力。它們相對更偏 OEM,而不是終端市場。

  • But basically, our whole EMG business is more OEM than end market. You have longer looks at your customers in terms of what you're going to be building in the future. So it's a pretty stable market. And we just think the growth in the case of Paragon over the next 3 years will be a little bit slower to get down on that gate because of some of the things that are going on. But we're pretty confident it's going to be a low double-digit grower over the next few years. So we think with those portfolio additions, they're going to grow just a bit greater than the rate of our base portfolio.

    但基本上,我們整個 EMG 業務相對都更偏 OEM,而不是終端市場。你能更長期地觀察客戶未來要建置/生產什麼,因此這是一個相當穩定的市場。我們認為,就 Paragon 而言,未來3年的成長在一開始可能會稍微慢一點、需要一些時間進入軌道,因為目前有一些事情正在發生。但我們相當有信心,未來幾年它會是低雙位數成長。因此我們認為,隨著這些投資組合的加入,它們的成長率會略高於我們基礎投資組合的成長率。

  • Operator

    Operator

  • Our next question will come from Andrew Buscaglia of BNP Paribas Exane.

    下一個問題來自 BNP Paribas Exane 的 Andrew Buscaglia。

  • Kevin C. Coleman - VP of IR & Treasurer

    Kevin C. Coleman - VP of IR & Treasurer

  • Andrew, are you there?

    Andrew,你在線上嗎?

  • Andrew Edouard Buscaglia - Research Analyst

    Andrew Edouard Buscaglia - Research Analyst

  • Can you hear me, okay?

    你們聽得到我嗎?

  • Kevin C. Coleman - VP of IR & Treasurer

    Kevin C. Coleman - VP of IR & Treasurer

  • Yes, we hear you.

    是的,我們聽得到。

  • Fine, then let's go to the next caller, and Andrew can get back into the queue.

    好的,那我們先接下一位來電者,Andrew 可以再回到隊列中。

  • Operator

    Operator

  • Certainly. Moving forward. Our next question is going to come from Andrew Obin of Bank of America.

    當然。繼續往下。我們下一個問題來自美國銀行(Bank of America)的 Andrew Obin。

  • Andrew Burris Obin - MD

    Andrew Burris Obin - MD

  • Bill, congratulations.

    Bill,恭喜。

  • William Joseph Burke - Executive VP & CFO

    William Joseph Burke - Executive VP & CFO

  • Thank you. Appreciate it.

    謝謝。感激不盡。

  • Andrew Burris Obin - MD

    Andrew Burris Obin - MD

  • Yes. So just a little bit more color. You -- I think other automation/short-cycle companies expect second half rebound. Your comments sort of indicate something very similar. What kind of visibility do you have on that? And what gives you confidence that things are actually are going to turn in the second half? And I acknowledge that your view is very much consistent with what we hear from everybody else.

    是的。想再多了解一些細節。我想其他自動化/短週期公司都預期下半年反彈。你的評論看起來也非常類似。你們對此有什麼樣的能見度?是什麼讓你們有信心事情確實會在下半年轉好?我也承認,你們的看法與我們從其他人那裡聽到的非常一致。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. I think that in that second half for automation, in particular, we're conservative on the input that we're getting from our customers in the marketplace. And I think that for the entire segment, we're forecasting it to be up low single digits. So we're not out. If we just put in there what our customers are telling us it would be higher. So we've been -- it's a bit of conservative that we placed in it. And it's largely from talking to customers and understanding their inventory levels and it's the typical work that we do to set a plan for the year. And it's -- we think the -- we'll see a positive second half as those orders, those backlogs are depleted.

    是的。我認為在自動化方面,特別是下半年,我們對從市場與客戶那裡得到的訊息採取了保守的假設。我們對整個事業部門的預測是低個位數成長。所以我們並沒有——如果我們只是把客戶告訴我們的內容直接放進去,數字會更高。因此我們——在其中放入了一些保守性。這主要來自與客戶的對話、了解他們的庫存水位,以及我們為年度計畫所做的典型工作。我們認為——當那些訂單、那些在手訂單(backlogs)被消化後,下半年會看到正向表現。

  • Andrew Burris Obin - MD

    Andrew Burris Obin - MD

  • Excellent. And just maybe a follow-on building on that. You talked about sort of increasing investment, but are there business units that need to start expanding capacity? Where are you broadly in capacity utilization? And finally, as you are expanding capacity, what are you going to do differently about your supply chain and where you are putting this capacity versus maybe pre-COVID?

    很好。再追問一個延伸問題。你提到會增加投資,但是否有些事業單位需要開始擴充產能?你們整體的產能利用率大概在哪個水準?最後,當你們擴產時,針對供應鏈以及產能配置地點,相較於 COVID 之前,你們會做哪些不同的事情?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. I mean in terms of supply chain, we did a lot of work to eliminate the risks from China, and we did it actually before COVID. So we were well positioned during it. And I think the -- our supply chain is developing naturally around the different regions of the world, and it's not as China-centric because of that. So that's 1 item. I think that in terms of capacity, we put significant capacity investments in over the past few years. We're a low CapEx business. And it's not -- we don't have to come to you and get away from our typical 2% of sales. We did it within our 2% of sales guideline. We put incremental capacity in our Mexican facilities. We put incremental capacity in our Malaysian facilities. We put incremental capacity in our Serbian facilities.

    是的。就供應鏈而言,我們做了很多工作來消除來自中國的風險,而且其實是在 COVID 之前就做了,所以在疫情期間我們的布局很到位。我認為——我們的供應鏈正自然地圍繞全球不同區域發展,因此不再那麼以中國為中心,這是第一點。第二,就產能而言,過去幾年我們投入了相當多的產能投資。我們是一個低資本支出(CapEx)的企業。而且——我們不需要來找你們、也不需要偏離我們典型的「營收的2%」水準;我們是在2%營收的指引內完成的。我們在墨西哥廠區增加了額外產能,在馬來西亞廠區增加了額外產能,在塞爾維亞廠區也增加了額外產能。

  • So I think we're pretty -- we have an asset-light business model, and we can usually ramp-up pretty quickly, and we have the flexibility to reduce cost very quickly. So that's one of the advantages of the AMETEK model with our low CapEx environment. We can grow sales and adjust sales on the downside without big capacity investments or without stringent investments when we downsize. So we're in excellent position to grow, and we've done all that work over the past few years or so. I feel really confident that we're going to be able to keep up with the growth through the next growth cycle.

    所以我認為我們相當——我們採取輕資產(asset-light)的商業模式,通常可以很快地提升產能,而且也具備非常快速降成本的彈性。這是 AMETEK 模式在低 CapEx 環境下的優勢之一。我們可以在不需要大量產能投資的情況下擴大銷售,也能在銷售下行時調整,而在縮編時也不需要嚴苛的投資。因此我們處於極佳的成長位置,而這些工作我們在過去幾年左右都已完成。我非常有信心,我們將能在下一個成長週期中持續跟上成長需求。

  • Operator

    Operator

  • Our next question is coming from Brett Linzey of Mizuho.

    我們的下一個問題來自瑞穗(Mizuho)的 Brett Linzey。

  • Brett Logan Linzey - Executive Director

    Brett Logan Linzey - Executive Director

  • Congratulations to everyone. I wanted to come back to the pruning comment on Paragon. So you indicated you're running down some of the less profitable areas, makes sense. I guess in the context of the broader portfolio, as you continue to shift towards this higher growth, higher-margin areas, is there more pruning to do on the other side in the context of the total AMETEK portfolio?

    恭喜各位。我想回到你們對 Paragon 的修剪(pruning)評論。你們表示正在縮減一些獲利較低的領域,這很合理。我想在更廣泛的投資組合脈絡下,隨著你們持續轉向這些更高成長、更高毛利的領域,在整體 AMETEK 投資組合的角度,另一端是否還有更多需要修剪的地方?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • This pruning process is something that we do with just about every new acquisition. So this is not new. And Paragon is a little bigger business, and we're going to be careful with it, but it's something that we do all the time. So all M&A deals will go through this process. Paragon is going to be going through in the first half. And we look at our own portfolio, and we do that kind of thing all the time. So yes, it can continue, and we're pretty good at that portfolio rationalization things.

    這個修剪流程幾乎是我們對每一筆新併購都會做的事情。所以這不是新鮮事。Paragon 的業務規模稍大,我們會謹慎處理,但這是我們一直在做的事。因此所有的併購交易都會經過這個流程。Paragon 會在上半年進行。我們也會檢視自有投資組合,這類事情我們一直都在做。所以是的,這可以持續進行,而且我們在投資組合合理化方面做得相當不錯。

  • Do you have another question, Brett?

    Brett,你還有其他問題嗎?

  • Brett Logan Linzey - Executive Director

    Brett Logan Linzey - Executive Director

  • Yes. And then just a second question on OpEx versus CapEx. I guess as you look at the customer spending environment for this year, and if you were to hone in on just those capital spending intensive businesses, have the planning assumptions or the tone changed in the last few months in that capital -- the capital spending type businesses at all?

    有。第二個問題是關於營運支出(OpEx)與資本支出(CapEx)。我想在你們看今年客戶支出環境時,如果聚焦在那些資本支出密集型的業務,過去幾個月在資本——也就是資本支出類型業務的規劃假設或語氣上,有沒有任何改變?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • In the U.S., there's a record number of projects from clean energy, power grid, semiconductor, they're just at a different level than they've been before. And a lot of that is from the government spending and backing. So that's largely continued. And at some point, it's going to provide an optimistic playing field for a lot of people in the industry. And I don't think we have that kind of upside built into our model right now, but it's -- there's planning going on with those projects right now. And that particular dynamic about the U.S. spending is driving the typical projects. So we're tracking to a very high number.

    在美國,來自潔淨能源、電網、半導體的專案數量創下紀錄,水準與以往不同。其中很大一部分來自政府支出與支持。因此這在很大程度上仍在延續。到某個時間點,這將為產業中的許多人提供一個更樂觀的競爭環境。我不認為我們目前的模型把那種上行空間納入,但——這些專案現在正在進行規劃。而美國支出這個特定動態正在推動典型專案。因此我們正在追蹤到一個非常高的數量。

  • Operator

    Operator

  • Our next question will come from Joe Giordano at TD Cowen.

    我們的下一個問題來自 TD Cowen 的 Joe Giordano。

  • Joseph Craig Giordano - MD & Senior Analyst

    Joseph Craig Giordano - MD & Senior Analyst

  • So a lot of companies are seeing -- have seen orders kind of decline organically for multiple quarters now. And predominantly, it's all attributed to inventory adjustment and supply chain, and hardly anyone has said anything about underlying conditions not being fine. So just curious if -- one, if you would agree with that. And two, if it worries you that everyone is seeing order declines and no one is saying anything is happening other than supply chain adjustments?

    很多公司看到——已經看到訂單在多個季度以來出現有機下滑。而且主要都歸因於庫存調整與供應鏈,幾乎沒有人提到基本面狀況不佳。所以我想請教:第一,你是否同意這種看法?第二,大家都看到訂單下滑,但沒有人說除了供應鏈調整之外還有其他事情在發生,這會讓你擔心嗎?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • It really doesn't because it's 100-year pandemic. I mean you saw what happened. The supply chains were broken. People put inventory in place. And as I just got done talking to the last call, the project business is so strong. So we have a similar view. We're -- our businesses in health care, Aerospace & Defense, Power and energy are performing well. They have a lot of projects. And we just think that we've going to work off the inventory, and then there's going to be a return to more typical growth for the industrial market.

    其實不會,因為這是百年一遇的疫情。你也看到發生了什麼事:供應鏈被打斷,人們建立了庫存。正如我剛才在上一通電話中談到的,專案型業務非常強勁。所以我們的看法類似。我們——我們在醫療保健、航太與國防、電力與能源的業務表現良好,手上有很多專案。我們認為庫存會被消化掉,之後工業市場會回到更典型的成長。

  • I mean, at the end of the day, though, nobody knows. And if we run into a recession, we have good muscle memory in that area. So we'll be able to react as we always react, and we can run our business appropriately. And in fact, select businesses have already been doing that during '23 margins in our automation business. Those people did a great job of removing excess costs from the business. So we're pretty good at reacting. But right now, we don't see that. We see the inventory being worked off, mainly in our OEM businesses and looking toward the future, we're optimistic with the number of new projects we have in the future.

    我的意思是,歸根結底,沒有人知道。如果我們遇到衰退,我們在這方面有很好的「肌肉記憶」。所以我們能像以往一樣做出反應,並適當地經營業務。事實上,在 2023 年,我們自動化業務中的部分事業已經在這麼做了——那些團隊在移除業務中的多餘成本方面做得很棒。所以我們很擅長應對。但目前我們沒有看到那種情況。我們看到的是庫存正在被消化,主要在我們的 OEM 業務中;展望未來,基於我們未來的新專案數量,我們保持樂觀。

  • Operator

    Operator

  • Next question is going to come from Steve Barger with KeyBanc Capital Markets.

    下一個問題來自 KeyBanc Capital Markets 的 Steve Barger。

  • Unidentified Analyst

    Unidentified Analyst

  • Dave, for the semi business, you mentioned your exposure to optics, which is great, but does that extend to advanced packaging applications, which are expected to show strong growth rates for the next couple of years? And if not, is getting specific exposure there? Something the team is looking at for M&A?

    Dave,針對半導體業務,你提到你們在光學方面的曝險,這很好。但這是否也延伸到先進封裝應用?先進封裝預期在未來幾年會有強勁的成長率。如果沒有,取得該領域的特定曝險是否是團隊在併購(M&A)上正在評估的方向?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. We have a little bit of exposure to advanced packaging, but it's spread across the business in different places, we're selling some components. So that's one of the items that our M&A teams are looking at, and we have exposure, but we'd like to have more.

    是的。我們在先進封裝方面有一些曝險,但分散在業務的不同部分,我們在賣一些零組件。所以這是我們併購團隊正在看的項目之一;我們有曝險,但希望能有更多。

  • Unidentified Analyst

    Unidentified Analyst

  • Okay. And then on the memory side, it seems like pricing is improving finally, and maybe fab utilization rates are starting to improve a bit. Is that translating into product inflection for you yet? Or is there still inventory that needs to be cleared on the memory side specifically?

    好的。那在記憶體方面,看起來價格終於在改善,晶圓廠稼動率可能也開始回升一些。這是否已經轉化為你們的產品拐點?還是說在記憶體端仍有庫存需要清理,特別是在記憶體這一塊?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. I think that market on the memory side, that market is pretty much bottomed. So I don't think there's -- when that ticks up, there's going to be a -- I think that's immediately going to flow to the bottom line. I think the inventory there is mainly cleared out.

    是的。我認為記憶體端的市場基本上已經觸底。所以我不認為還有——當它開始回升時,我認為會——我認為那會立刻反映到獲利(bottom line)上。我認為那邊的庫存主要已經清得差不多了。

  • Operator

    Operator

  • Our next question comes from Andrew Buscaglia of BNP Paribas Exane.

    我們的下一個問題來自 BNP Paribas Exane 的 Andrew Buscaglia。

  • Kevin C. Coleman - VP of IR & Treasurer

    Kevin C. Coleman - VP of IR & Treasurer

  • Go ahead, Andrew.

    請說,Andrew。

  • Operator

    Operator

  • Okay. I'm going to release Andrew's line.

    好的。我將釋放 Andrew 的線路。

  • And our next question will be coming from Rob Mason of Baird.

    我們的下一個問題將來自 Baird 的 Rob Mason。

  • Robert W. Mason - Senior Research Analyst

    Robert W. Mason - Senior Research Analyst

  • Yes. And I'll offer my congratulations as well, Bill. Dave, a lot of questions have been asked. I just circle back to the Process business. You talked about that going to be up low single digits for the year. There's a lot in there from a business mix and market standpoint. Could you maybe speak to anything that could outperform that low single digits or anything that would stand out? And just for clarity sake, what is the actual Process industry exposure there now?

    是的。我也要向你致上恭喜,Bill。Dave,已經問了很多問題。我想回到 Process 業務。你提到今年會是低個位數成長。這裡面在業務組合與市場面有很多因素。你能否談談有哪些可能優於這個低個位數的部分,或有哪些特別突出的地方?另外為了釐清,目前實際的 Process 產業曝險是多少?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. The process is -- a broader look at our Process & Analytical Instruments business and the specific Process industry would be more the Process & Analytical Instruments business, which is a good part of it. And I think that what you're going to see there is our energy businesses are perhaps -- they grew nicely in Q4, and they have a good outlook for 2024. I think we sell a lot of business to Asia and China is -- I told you, we talked about it being flat. So that's something that we're concerned within the year for Process.

    是的。Process——更廣泛來看,我們的 Process & Analytical Instruments(製程與分析儀器)業務,而特定的 Process 產業曝險會更多體現在 Process & Analytical Instruments 業務中,這占了相當一部分。我認為你會看到的是,我們的能源業務在第四季成長不錯,且對 2024 年有良好展望。我們在亞洲有很多銷售,而中國——我跟你說過,我們談到它可能持平。因此這是我們在今年 Process 業務中會關注的點。

  • But as long as we keep developing state-of-the-art projects that are unmatched by our competitors, we're going to be fine in Process and as evidenced by our CAMECA, Zygo, broader UPT, broader MAD sales. So it's the research market, it's the optics market that are driving the business, and there are some medical applications in our Rauland business that are in that segment. So there's a mix of different end market drivers. But when you look at the thing in total, we're calling it up low single digits this year. And again, the international parts of the business will be weaker than the U.S. parts.

    但只要我們持續開發最先進、競爭對手無法匹敵的專案,我們在 Process 方面就會沒問題,這也可從我們 CAMECA、Zygo、更廣泛的 UPT、更廣泛的 MAD 銷售得到印證。所以推動業務的是研究市場與光學市場,而我們 Rauland 業務在該分部也有一些醫療應用。因此終端市場驅動因素是多元混合的。但整體來看,我們今年的指引是低個位數成長。同樣地,國際業務的表現會弱於美國業務。

  • Operator

    Operator

  • And I'm showing no further questions. I would now like to turn the conference back to Kevin Coleman for closing remarks.

    我這邊顯示沒有更多問題。現在我想把會議交回給 Kevin Coleman 做結語。

  • Kevin C. Coleman - VP of IR & Treasurer

    Kevin C. Coleman - VP of IR & Treasurer

  • Thank you again, Tanya, and thank you, everyone, for joining us for the conference call today. And as a reminder, a replay of the webcast can be accessed in the Investors section of ametek.com. Have a great day.

    再次感謝 Tanya,也感謝各位今天參加我們的電話會議。提醒一下,網路直播的重播可在 ametek.com 的投資人(Investors)專區收看。祝各位有美好的一天。

  • Operator

    Operator

  • This concludes today's conference call. Thank you for participating. You may now disconnect.

    今天的電話會議到此結束。感謝各位參與。您現在可以掛線。